liveBook · Manning

Structure-based drug design

As explained in Build AI Drug Discovery Pipelines

Structure-based drug design is a drug-design approach that uses three-dimensional molecular structures and interactions to guide compound discovery and optimization.

Structure-based drug design uses a biological target’s three-dimensional structure to guide the discovery and optimization of molecules that bind and modulate it. Molecular docking estimates binding poses and scores, enabling computational screening of large compound libraries. section 9.0 section 9.1

A practical structure-based screening workflow typically:

  • Obtains and prepares a protein structure determined through X-ray crystallography, cryo-EM, NMR, or another structural method. section 9.1
  • Prepares ligands, defines a binding site, docks compounds, and analyzes predicted protein–ligand interactions. section 9.4
  • Uses docking scores to prioritize promising candidates, while treating those scores as approximate rather than definitive binding measurements. section 9.0
  • Scales screening with a surrogate model and active learning, docking selected compounds while predicting scores for the rest. section 9.0 section 9.4
Figure 2.1 Virtual screening pipelines are often hierarchical, proceeding with a broad, large number of compounds through simpler, less restrictive, and computationally cheaper processes to whittle down the quantity of compounds. If the 3D structure of the target is not defined, we’re restricted to ligand-based virtual screening. If it is defined, then we can explore structure-based virtual screening, potentially as a downstream component to ligand-based virtual screening.

Use the hierarchical pipeline to compare inexpensive broad filtering with downstream structure-based screening when a defined target structure is available. section 2.1.1

Active learning for kinase screening

A complete workflow can prepare an EGFR target and ligands, dock them with AutoDock Vina, and analyze interaction fingerprints. For a VEGFR-2 library identified by PDB ID 4AG8, active learning recovered 73 of the top 100 compounds after ten iterations while docking only a small fraction of the library. section 9.4

How Build AI Drug Discovery Pipelines covers it

How deep it goes
Descends from target preparation through docking, interaction analysis, surrogate modeling, and active-learning loops, while retaining approximate scoring limits.
Examples
Demonstrates EGFR docking, VEGFR-2 screening with PDB ID 4AG8, AutoDock Vina, interaction fingerprints, and neural-network surrogate models.
What it assumes
Assumes a defined three-dimensional target structure for structure-based methods and distinguishes this case from ligand-based screening.
What you can do after
Build a protein–ligand docking workflow and apply active learning to prioritize candidates while reducing exhaustive docking.
How it connects
Connects molecular docking, structure-based virtual screening, deep learning, active learning, and free energy perturbation.

Related concepts

This explainer was generated by Manning's knowledge graph from the text of Build AI Drug Discovery Pipelines. The section links point to the parts of the book it draws on.